Current advances and challenges in the development of acinetobacter vaccines

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 10, 2015, Pages 2495-2500

  Chen, Wangxue ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b BROCK UNIVERSITY   (Canada)

Author keywords

Acinetobacter; Animal model; Antigen selection; Correlate of protection; Vaccine

Indexed keywords

ACINETOBACTER VACCINE; B7 ANTIGEN; BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; CARBOHYDRATE ANTIGEN; CD86 ANTIGEN; GLUCOSAMINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLY NACETYL BETA (1 6) GLUCOSAMINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CORRELATION ANALYSIS; HEALTHCARE ASSOCIATED INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; INFLAMMATION; INNATE IMMUNITY; MULTIDRUG RESISTANCE; NONHUMAN; VACCINATION; ACINETOBACTER INFECTIONS; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; PRECLINICAL STUDY; PROCEDURES; TRENDS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE;

EID: 84953879983     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1052354     Document Type: Article

References (53)

1. Paterson DL, Harris PN. The New Acinetobacter Equation: Hypervirulence plus Antibiotic Resistance Equals Big Trouble. Clin Infect Dis 2015; 61:155-6; PMID:25824816
2. Perez F, Bonomo RA. Vaccines for Acinetobacter baumannii: thinking “out of the box”. Vaccine 2014;32:2537-9; PMID:24662709; http://dx.doi.org/10.1016/j.vaccine.2014.03.031
3. Dallo SF, Weitao T. Insights into acinetobacter war-wound infections, biofilms, and control. Adv Skin Wound Care 2010; 23:169-74; PMID:20299843; http://dx.doi.org/10.1097/01.ASW.0000363527.08501.a3
4. Falagas ME, Karveli EA. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infect 2007; 13:117-9; PMID:17328722; http://dx.doi.org/10.1111/j.1469-0691.2006.01596.x
5. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538-82; PMID:18625687; http://dx.doi.org/10.1128/CMR.00058-07
6. Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 2009; 73:355-63;
7. PMID:19700220; http://dx.doi.org/10.1016/j.jhin.2009.03.032
8. McConnell MJ, Dominguez-Herrera J, Smani Y, Lopez-Rojas R, Docobo-Perez F, Pachon J. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun 2011; 79:518-26; PMID:20974823; http://dx.doi.org/10.1128/IAI.00741-10
9. McConnell MJ, Pachon J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 2010; 29:5; PMID:21044668; http://dx.doi.org/10.1016/j. vaccine.2010.10.052
10. McConnell MJ, Rumbo C, Bou G, Pachon J. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 2011; 29:5705-10; PMID:21679737; http://dx.doi.org/10.1016/j.vaccine.2011.06.001
11. Gening ML, Maira-Litran T, Kropec A, Skurnik D, Grout M, Tsvetkov YE, Nifantiev NE, Pier GB. Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens. Infect Immun 2010; 78:764-72; PMID:19948836; http://dx.doi.org/10.1128/IAI.01093-09
12. Bentancor LV, O’Malley JM, Bozkurt-Guzel C, Pier GB, Maira-Litran T. Poly-N-acetyl-beta-(1-6)-glucos-amine is a target for protective immunity against Acinetobacter baumannii infections. Infect Immun 2012; 80:651-6; PMID:22104104; http://dx.doi.org/10.1128/IAI.05653-11
13. Bentancor LV, Routray A, Bozkurt-Guzel C, Camacho-Peiro A, Pier GB, Maira-Litran T. Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections. Infect Immun 2012; 80:3381-8; PMID:22825448; http://dx.doi.org/10.1128/IAI.06096-11
14. Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, Doi Y, Adams MD, Russo TA, Spell-berg B. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PloS one 2012; 7:e29446; PMID:22253723; http://dx.doi.org/10.1371/journal.pone.0029446
15. Lin L, Tan B, Pantapalangkoor P, Ho T, Hujer AM, Taracila MA, Bonomo RA, Spellberg B. Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine 2013; 31:313-8; PMID:23153442; http://dx.doi.org/10.1016/j.vaccine.2012.11.008
16. Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, St Michael F, Vinogradov EV, Spellberg B, Luke-Marshall NR, Campagnari AA. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun 2013; 81:915-22; PMID:23297385; http://dx.doi.org/10.1128/IAI.01184-12
17. KuoLee R, Harris G, Yan H, Xu HH, Conlan WJ, Patel GB, Chen W. Intranasal immunization protects against Acinetobacter baumannii-associated pneumonia in mice. Vaccine 2015; 33:260-7; PMID:24699469; http://dx.doi.org/10.1016/j.vaccine.2014.02.083
18. Fattahian Y, Rasooli I, Mousavi Gargari SL, Rahbar MR, Darvish Alipour Astaneh S, Amani J. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap). Microb Pathog 2011; 51:402-6; PMID:21946278; http://dx.doi.org/10.1016/j.micpath.2011.09.004
19. Chiang MH, Sung WC, Lien SP, Chen YZ, Lo AF, Huang JH, Kuo SC, Chong P. Identification of novel vaccine candidates against Acinetobacter baumanniiusing reverse vaccinology. Hum Vaccin Immunother 2015; 11(4):1065-73; PMID:25751377
20. Huang W, Yao Y, Long Q, Yang X, Sun W, Liu C, Jin X, Li Y, Chu X, Chen B, et al. Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models. PloS One 2014; 9:e100727; PMID:24956279; http://dx.doi.org/10.1371/journal.pone.0100727
21. Cross AS, Chen WH, Levine MM. A case for immunization against nosocomial infections. J Leukocyte Biol 2008; 83:483-8; PMID:18070981; http://dx.doi.org/10.1189/jlb.0607379
22. Pachon J, McConnell MJ. Considerations for the development of a prophylactic vaccine for Acinetobacter baumannii. Vaccine 2014; 32:2534-6;PMID:24188749; http://dx.doi.org/10.1016/j.vaccine.2013.10.064
23. Garcia-Quintanilla M, Pulido MR, McConnell MJ. First steps towards a vaccine against Acinetobacter baumannii. Curr Pharm Biotechnol 2013; 14:897-902; PMID:24372252; http://dx.doi.org/10.2174/1389201014666131226123511
24. Fowler VG, Jr., Proctor RA. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect 2014; 20(Suppl 5):66-75; PMID:24476315; http://dx.doi.org/10.1111/1469-0691.12570
25. Leuzzi R, Adamo R, Scarselli M. Vaccines against Clos-tridium difficile. Hum Vaccin Immunother 2014; 10:1466-77; PMID:24637887; http://dx.doi.org/10.4161/hv.28428
26. Garcia-Quintanilla M, Pulido MR, Pachon J, McConnell MJ. Immunization with lipopolysaccharide-deficient whole cells provides protective immunity in an experimental mouse model of Acinetobacter baumannii infection. PloS One 2014; 9:e114410; PMID:25485716; http://dx.doi.org/10.1371/journal.pone.0114410
27. Vella M, Pace D. Glycoconjugate vaccines: an update. Expert Opin Biol Ther 2015; 15:529-46;PMID:25496172; http://dx.doi.org/10.1517/14712598.2015.993375
28. Kinsella RL, Scott NE, Feldman MF. Clinical implications of glycoproteomics for Acinetobacter baumannii. Expert Rev Proteomics 2015; 12:3;PMID:25496064; http://dx.doi.org/10.1586/14789450.2015.987756
29. Hu D, Liu B, Dijkshoorn L, Wang L, Reeves PR. Diversity in the major polysaccharide antigen of Acinetobacter baumannii assessed by DNA sequencing, and development of a molecular serotyping scheme. PloS One 2013; 8:e70329; PMID:23922982; http://dx.doi.org/10.1371/journal.pone.0070329
30. Traub WH. Serotyping of clinical isolates of Acinetobacter baumannii and genospecies 13 capable of growth at 44 C: Detection of four new serovars. Zentralblatt fur Bakteriologie 1998; 288:175-80; PMID:9809399
31. Chopra S, Ramkissoon K, Anderson DC. A systematic quantitative proteomic examination of multidrug resistance in Acinetobacter baumannii. J Proteomics 2013; 84:17-39; PMID:23542354; http://dx.doi.org/10.1016/j.jprot.2013.03.008
32. Fajardo Bonin R, Chapeaurouge A, Perales J, da Silva JG, Jr., do Nascimento HJ, D’Alincourt Carvalho Assef AP, Moreno Senna JP. Identification of immunogenic proteins of the bacterium Acinetobacter baumannii using a proteomic approach. Proteomics Clin Appl 2014; 8:916-23; PMID:24899143; http://dx.doi.org/10.1002/prca.201300133
33. Lee JS, Kim JW, Choi CH, Lee WK, Chung HY, Lee JC. Anti-tumor activity of Acinetobacter baumannii outer membrane protein A on dendritic cell-based immunotherapy against murine melanoma. J Microbiol 2008; 46:221-7; PMID:18545973; http://dx.doi.org/10.1007/s12275-008-0052-z
34. Goel VK, Kapil A. Monoclonal antibodies against the iron regulated outer membrane Proteins of Acinetobacter baumannii are bactericidal. BMC Microbiol 2001; 1:16; PMID:11532195; http://dx.doi.org/10.1186/1471-2180-1-16
35. Hosseingholi EZ, Rasooli I, Gargari SL. In silico analysis of Acinetobacter baumannii phospholipase D as a subunit vaccine candidate. Acta Biotheoretica 2014; 62:455-78; PMID:24957752; http://dx.doi.org/10.1007/s10441-014-9226-8
36. Moriel DG, Beatson SA, Wurpel DJ, Lipman J, Nimmo GR, Paterson DL, Schembri MA. Identification of novel vaccine candidates against multidrug-resistant Acinetobacter baumannii. PloS One 2013; 8: e77631; PMID:24116234; http://dx.doi.org/10.1371/journal.pone.0077631
37. Breslow JM, Meissler JJ, Jr., Hartzell RR, Spence PB, Truant A, Gaughan J, Eisenstein TK. Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance. Infect Immun 2011; 79:3317-27; PMID:21576323; http://dx.doi.org/10.1128/IAI.00069-11
38. van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun 2007; 75:5597-608; PMID:17908807; http://dx.doi.org/10.1128/IAI.00762-07
39. Bruhn KW, Pantapalangkoor P, Nielsen T, Tan B, Junus J, Hujer KM, Wright MS, Bonomo RA, Adams MD, Chen W, et al. Host Fate is Rapidly Determined by Innate Effector-Microbial Interactions During Acinetobacter baumannii Bacteremia. J Infect Dis 2015; 211:1296-305; PMID:25378635
40. Qiu H, KuoLee R, Harris G, Van Rooijen N, Patel GB, Chen W. Role of macrophages in early host resistance to respiratory Acinetobacter baumannii infection. PLoS One 2012; 7:e40019; PMID:22768201; http://dx.doi.org/10.1371/journal.pone.0040019
41. Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin JH, Kim JM, Lee YC, Seol SY, Cho DT, et al. Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins. FEMS Microbiol Lett 2009; 301:224-31; PMID:19878322; http://dx.doi.org/10.1111/j.1574-6968.2009.01820.x
42. King LB, Swiatlo E, Swiatlo A, McDaniel LS. Serum resistance and biofilm formation in clinical isolates of Acinetobacter baumannii. FEMS Immunol Med Microbiol 2009; 55:414-21; PMID:19220466; http://dx.doi.org/10.1111/j.1574-695X.2009.00538.x
43. Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, Schultz LW, Umland TC, Campagnari AA. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun 2010; 78:3993-4000; PMID:20643860; http://dx.doi.org/10.1128/IAI.00366-10
44. Qiu H, KuoLee R, Harris G, Chen W. High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils. Microbes Infect 2009; 11:946-55; PMID:19573619; http://dx.doi.org/10.1016/j.micinf.2009.06.003
45. Trzcinski K, Thompson CM, Srivastava A, Basset A, Malley R, Lipsitch M. Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4C T cells. Infect Immun 2008; 76:2678-84; PMID:18391006; http://dx.doi.org/10.1128/IAI.00141-08
46. Leef M, Elkins KL, Barbic J, Shahin RD. Protective immunity to Bordetella pertussis requires both B cells and CD4(C) T cells for key functions other than specific antibody production. J Exp Med 2000; 191:1841-52; PMID:10839801; http://dx.doi.org/10.1084/jem.191.11.1841
47. Bist P, Dikshit N, Koh TH, Mortellaro A, Tan TT, Sukumaran B. The Nod1, Nod2, and Rip2 axis contributes to host immune defense against intracellular Acinetobacter baumannii infection. Infect Immun 2014; 82:1112-22; PMID:24366254; http://dx.doi.org/10.1128/IAI.01459-13
48. Hartzell JD, Kim AS, Kortepeter MG, Moran KA. Acinetobacter pneumonia: a review. MedGenMed 2007; 9:4; PMID:18092011
49. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother 1997; 41:345-51; PMID:9021190
50. Harris G, Kuo Lee R, Lam CK, Kanzaki G, Patel GB, Xu HH, Chen W. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother 2013; 57:3601-13; PMID:23689726; http://dx.doi.org/10.1128/AAC.00944-13
51. Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, Gancz HY, Corey BW, Moon JK, Si Y, et al. AB5075, a highly virulent isolate of Acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. mBio 2014; 5:e01076-14; PMID:24865555; http://dx.doi.org/10.1128/mBio.01076-14
52. Russo TA, Beanan JM, Olson R, MacDonald U, Luke NR, Gill SR, Campagnari AA. Rat pneumonia and soft-tissue infection models for the study of Acineto-bacter baumannii biology. Infect Immun 2008; 76:3577-86; PMID:18541654; http://dx.doi.org/10.1128/IAI.00269-08
53. Li ZT, Zhang RL, Bi XG, Xu L, Fan M, Xie D, Xian Y, Wang Y, Li XJ, Wu ZD, et al. Outer membrane vesicles isolated from two clinical Acinetobacter baumannii strains exhibit different toxicity and proteome characteristics. Microb Pathog 2015; 81:46-52; PMID:25773772; http://dx.doi.org/10.1016/j.micpath.2015.03.009